PRVB Projected Dividend Yield
Provention Bio Inc ( NASDAQ : PRVB )Provention Bio is a clinical stage biopharmaceutical company. Co.'s primary asset, TZIELD, is approved to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adult and pediatric patients aged eight years and older with Stage 2 T1D. Co. is also developing TZIELD for use in Stage 3 newly diagnosed T1D patients, for which Co. has an ongoing phase three clinical trial, the PROTECT study. Co.'s product portfolio also include: PRV-3279, which is a humanized bispecific scaffold molecule targeting the B-cell surface proteins, an inhibitory Fc receptor for the treatment of systemic lupus erythematosus and for the prevention of immunogenicity of biotherapeutics such as those used in gene therapy. 20 YEAR PERFORMANCE RESULTS |
PRVB Dividend History Detail PRVB Dividend News PRVB Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |